SLAMF7-CAR T细胞可清除骨髓瘤并对SLAMF7阳性正常淋巴细胞产生选择性同室相残
本研究将T细胞通过表达源自huLuc63抗体(埃罗妥珠单抗)的嵌合抗原受体(CAR)靶向SLAMF7,证实来自患者和健康供者的SLAMF7-CAR T细胞具有强效抗骨髓瘤反应性,可快速裂解初治和复发/难治原代骨髓瘤细胞,并在小鼠异种移植模型中单次给药使髓内和髓外骨髓瘤表现消退;同时SLAMF7-CAR T细胞对SLAMF7高表达的正常NK细胞、CD4+和CD8+ T细胞及B细胞诱导选择性同室相残,但保留SLAMF7低/阴性部分及功能性淋巴细胞(包括病毒特异性T细胞)。
要点
- SLAMF7在初治和复发/难治骨髓瘤患者的恶性浆细胞上呈均匀高水平表达。
- SLAMF7-CAR T细胞在体外快速裂解初治和复发/难治原代骨髓瘤细胞。
- 小鼠异种移植模型中单次给药SLAMF7-CAR T细胞使髓内和髓外骨髓瘤表现消退。
核心结论
- SLAMF7-CAR T细胞疗法可能是治疗多发性骨髓瘤的有效方法,并为了解靶向SLAMF7对正常淋巴细胞区室的影响提供了新见解。
研究设计与样本
- 本研究为体外和体内临床前研究,使用来自患者和健康供者的SLAMF7-CAR T细胞,并在小鼠异种移植模型中进行体内评估。
主要发现
- 在初治和既往接受过蛋白酶体抑制剂及免疫调节药物治疗的复发/难治骨髓瘤患者中,恶性浆细胞上SLAMF7呈均匀高水平表达。
- SLAMF7-CAR T细胞在体外对初治和复发/难治原代骨髓瘤细胞均诱导快速细胞溶解。
- 在小鼠异种移植模型中,单次给予SLAMF7-CAR T细胞使髓内和髓外骨髓瘤表现消退。
- SLAMF7-CAR T细胞对SLAMF7高表达的NK细胞、CD4+和CD8+ T细胞及B细胞诱导选择性同室相残,但保留各细胞亚群中SLAMF7低/阴性部分及功能性淋巴细胞(包括病毒特异性T细胞)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. In this study, we redirected the specificity of T cells to SLAMF7 through expression of a chimeric antigen receptor (CAR) derived from the huLuc63 antibody (elotuzumab) and demonstrate that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. We confirmed uniform, high-level expression of SLAMF7 on malignant plasma cells in previously untreated and in relapsed/refractory (R/R) myeloma patients who had received previous treatment with proteasome inhibitors and immunomodulatory drugs. Consequently, SLAMF7-CAR T cells conferred rapid cytolysis of previously untreated and R/R primary myeloma cells in vitro. In addition, a single administration of SLAMF7-CAR T cells led to resolution of medullary and extramedullary myeloma manifestations in a murine xenograft model in vivo. SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. After modification with the SLAMF7-CAR, both CD8+ and CD4+ T cells rapidly acquired and maintained a SLAMF7- phenotype and could be readily expanded to therapeutically relevant cell doses. We analyzed the recognition of normal lymphocytes by SLAMF7-CAR T cells and show that they induce selective fratricide of SLAMF7+/high NK cells, CD4+ and CD8+ T cells, and B cells. Importantly, however, the fratricide conferred by SLAMF7-CAR T cells spares the SLAMF7-/low fraction in each cell subset and preserves functional lymphocytes, including virus-specific T cells. In aggregate, our data illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against multiple myeloma and provide novel insights into the consequences of targeting SLAMF7 for the normal lymphocyte compartment.
引用
- Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 2017. PMID: 29089311. doi:10.1182/blood-2017-04-778423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。